

Docket No. 2519-US-NP

RECEIVED  
CENTRAL FAX CENTER

FEB 08 2007

## 2. Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-14 (*cancelled*)

15. (*Currently amended*) A method of screening a test compound comprising the steps of:

a. forming a composition comprising

(i) a first isolated protein, comprising a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:2;
- (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;
- (c) a fragment of the polypeptide of SEQ ID NO:2; or
- (d) a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO:1;

wherein said fragment of (i)(c) and said polypeptides of (i)(d) bind SEQ ID NO:4;

(ii) a second isolated protein, comprising a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:4;
- (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4; or
- (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;

(iii) a test compound; and

b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from 1.53 x 10<sup>-9</sup> to 2.2 x 10<sup>-9</sup>;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

Docket No. 2519-US-NP

16. (*Previously presented*) The method of claim 15 wherein at least one of the proteins of (i) and the proteins of (ii) is labeled with a detectable moiety.
17. (*Previously presented*) The method of claim 15 wherein both the proteins of (i) and (ii) are soluble.
18. (*Previously presented*) The method of claim 17 wherein both the soluble protein of (i) and the soluble protein of (ii) are labeled with a detectable moiety.
19. (*Previously presented*) The method of claim 15 wherein the test compound is an antibody.
20. (*Previously presented*) The method of claim 19 wherein the antibody is a humanized antibody.
21. (*Previously presented*) The method of claim 15 wherein the composition is formed by adding the test compound to the protein of (i) and the protein of (ii).
22. (*Previously presented*) The method of claim 15 wherein step (b) comprises determining a dissociation constant of the interaction of the protein of (i) with the protein of (ii).
23. (*Previously presented*) The method of claim 15 wherein step (b) comprises assessing activation of the protein of (i) in a cell.
24. (*Previously presented*) The method of claim 23 wherein assessing activation of the protein of (i) in a cell is measured by calcium influx.
25. (*Previously presented*) The method of claim 15 wherein the protein of (ii) is a polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or a polypeptide comprising amino acids 73-285 of SEQ ID NO:4.

Docket No. 2519-US-NP

26. (*Previously presented*) The method of claim 25 wherein the polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or the polypeptide comprising amino acids 73-285 of SEQ ID NO:4 further comprises a leucine zipper domain.

27. (*Previously presented*) The method of claim 15 wherein the protein of (i) is a polypeptide comprising amino acids 2-166 of SEQ ID NO:2.

28. (*Previously presented*) The method of claim 27 wherein the polypeptide comprising amino acids 2-166 of SEQ ID NO:2 further comprises a Fc domain.

29. (*Currently amended*) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) an isolated protein selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:2;
    - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2; and
    - (c) a fragment of the polypeptide of SEQ ID NO:2; wherein said fragment binds SEQ ID NO:4;
  - (ii) the polypeptide of SEQ ID NO:4; and
  - (iii) a test compound; and
- b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from  $1.53 \times 10^{-9}$  to  $2.2 \times 10^{-9}$ ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

30. (*Currently amended*) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) the polypeptide of SEQ ID NO:2;
  - (ii) an isolated protein selected from the group consisting of:

Docket No. 2519-US-NP

- (a) the polypeptide of SEQ ID NO:4;
- (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4;
- (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4; and
- (d) a fragment of the polypeptide of SEQ ID NO:4; wherein said fragment binds SEQ ID NO:2; and

(iii) a test compound; and

b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from  $1.53 \times 10^{-9}$  to  $2.2 \times 10^{-9}$ ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

31. (*Cancelled*)

32. (*Currently amended*) A method of screening a test compound comprising the steps of:

a. forming a composition comprising

- (i) the polypeptide of SEQ ID NO:2;
- (ii) the polypeptide of SEQ ID NO:4; and
- (iii) a test compound; and

b. assaying for the level of interaction of the polypeptide of (i) and the polypeptide of (ii), whrcin the affinity constant for protein (i) and protein (ii) is from  $1.53 \times 10^{-9}$  to  $2.2 \times 10^{-9}$ ;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.

33. (*Cancelled*)

34. (*Cancelled*)

Docket No. 2519-US-NP

35. (*Previously presented*) The method of claim 25, wherein the polypeptide comprising amino acids 123-285 of SEQ ID NO:4 or the polypeptide comprising amino acids 73-285 of SEQ ID NO:4 further comprises a Fc domain.

36. (*Cancelled*)

37. (*Previously presented*) The method of claim 19, wherein the antibody is human.

38. (*Previously presented*) The method of claim 19, wherein the antibody comprises a Fab fragment.

39. (*Previously presented*) The method of claim 19, wherein the antibody comprises a F(ab')<sub>2</sub> fragment.

40. (*Currently amended*) A method of screening a test compound comprising the steps of:

- a. forming a composition comprising
  - (i) a first isolated protein, comprising a polypeptide selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:2; or
    - (b) a polypeptide comprising amino acids 2-166 of SEQ ID NO:2;
  - (ii) a second isolated protein, comprising a polypeptide selected from the group consisting of:
    - (a) the polypeptide of SEQ ID NO:4;
    - (b) a polypeptide comprising amino acids 123-285 of SEQ ID NO:4;
    - (c) a polypeptide comprising amino acids 73-285 of SEQ ID NO:4;
    - (d) a fragment of the polypeptide of SEQ ID NO:4; or
    - (e) a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3;

Docket No. 2519-US-NP

wherein said fragment of (ii)(d) and said polypeptides of (ii)(e) bind SEQ ID NO:2; and

(iii) a test compound; and

b. assaying for the level of interaction of the protein of (i) and the protein of (ii), wherein the affinity constant for protein (i) and protein (ii) is from 1.53 x 10<sup>-9</sup> to 2.2 x 10<sup>-9</sup>;

such that if the level obtained in step (b) differs from that obtained in the absence of the test compound, a test compound that affects the interaction of the protein of (i) and the protein of (ii) is identified.